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Abstract Stem cell therapies hold the great promise and
interest for cardiac regeneration among scientists, clinicians
and patients. However, advancement and distillation of a
standard treatment regimen are not yet finalised. Into this
breach step recent developments in the imaging biosciences.
Thusfar,thesetechnicalandprotocolrefinementshaveplayed
a critical role not only in the evaluation of the recovery of
cardiac function but also in providing important insights into
the mechanism of action of stem cells. Molecular imaging, in
its many forms, has rapidly become a necessary tool for the
validation and optimisation of stem cell engrafting strategies
in preclinical studies. These include a suite of radionuclide,
magnetic resonance and optical imaging strategies to evaluate
non-invasivelythefateoftransplantedcells.Inthisreview,we
highlight the state-of-the-art of the various imaging techni-
ques for cardiac stem cell presenting the strengths and
limitations of each approach, with a particular focus on
clinical applicability.
Keywords Cell tracking.Stem cells.Myocardial
infarction.Heart failure.Molecular imaging
Introduction
In the last decade a great amount of research and clinical
interest has been directed at stem cells (SC) for their
potential to regenerate otherwise permanently damaged
tissues. Work with these pluripotent cells has begun to be
broadly explored, giving new hope for regenerative
approaches in the therapy of myocardial infarction (MI).
Early success in preclinical studies demonstrated that
stem cell-based therapy holds the potential to limit the
functional degradation of cardiac function after MI [1]. This
instigated clinical translation at a rapid pace (Table 1). Since
the first study in 2002 which showed safety and effective-
ness on intracoronary transplantation of autologous SC [2],
several randomised, controlled clinical trials have been
performed. Due to the absence of standardised protocols
(cell number, timing and route of injection, baseline patient
characteristics and techniques of evaluating cardiac func-
tion), results have been mixed. However, recent meta-
analyses have shown that improvement in ejection fraction
(EF), ventricular dimension and infarct area, despite being
modest, are statistically significant [3–5].
This field clearly benefited from the advancements in
imaging sciences as almost all clinical trials involved the
use of one or more imaging techniques to evaluate the
therapeutic efficacy of stem cell transplantion. Clinically
established techniques allow for the evaluation of myocar-
dial contractility, viability and perfusion, but do not provide
the direct visualisation of transplanted stem cells, therefore
their effective presence and viability can be only presumed.
Ideally, transplanted cells in the infarcted myocardium are
expected to survive engraftment, be self-renewing and
differentiate into cardiac cells (cardiomyocytes, endothelial
cells or smooth muscle cells) forming electromechanical
junctions with adjacent viable tissues. However, the long-
A. Ruggiero (*): J. Guenoun: G. P. Krestin:M. R. Bernsen
Department of Radiology,
Erasmus MC—University Medical Center,
Dr. Molewaterplein 50,
Rotterdam 3015GE, The Netherlands
e-mail: a.ruggiero@erasmusmc.nl
D. L. J. Thorek
Department of Radiology,
Memorial Sloan-Kettering Cancer Center,
New York, NY, USA
M. R. Bernsen
Department of Nuclear Medicine, Erasmus MC,
Rotterdam, The Netherlands
Eur Radiol (2012) 22:189–204
DOI 10.1007/s00330-011-2190-7term improvement appears to be most closely related to
paracrine effects rather than transdifferentiation of the cell
transplant and heart muscle regeneration [6].
Greatstrides inimaging techniques andtechnologies have
been made that enable the cellular and molecular imaging of
transplanted stem cells, their short and long term fate and in
some instances their viability and differentiation status.
Stem cells for cardiac repair
Currently adult stem cells, embryonic stem cells (ESC) and
induced pluripotent stem cells (iPS) can be used to
regenerate heart tissue. Adult stem cells comprise skeletal
myoblasts (SM), mesenchymal stem cells (MSC), bone
marrow- derived stem cells (BMC), endothelial (EPC) and
cardiac progenitor (CPC) cells. SM were the first option
to be used in stem cell transplant as they are available from
an autologous source (therefore lacking ethical or immu-
nogenicity issues), and have been demonstrated to provide
functional benefit after myocardial infarction in animals
[7]. However, in a recent clinical trial no sustained benefit
in the global EF was observed and increased number of
early postoperative arrhythmic events was reported [8].
BMC transplantation has been shown to improve heart
function in animal models [1, 9]. However, others have
identified that most of the cells injected adopted a mature
haematopoietic transformation and only a small number of
cardiomyocytes expressed the genetic markers of the trans-
planted cells [10, 11]. Mesenchymal stem cells (MSC)
constitute the stromal compartment of bone marrow and,
importantly, are not hematopoietic. These are able to
differentiate into a variety of cell types [12] and improvement
in whole heart function has been described in a swine model
of myocardial infarction [13]. Visceral and subcutaneous
adipose tissue have been shown to contain vascular/adipocyte
progenitor cells and adult multipotent mesenchymal cells
(adipose tissue-derived stromal cells [14]). ASC have been
reported to improve left ventricular function in animal models
of myocardial infarction [15]. The circulating endothelial
progenitor cells (EPC) represent a more accessible source of
autologous SC and have been used in clinical trials [16]. The
existence of a subpopulation of resident cardiac SC (RCSC)
has been reported that is self-renewing, clonogenic and
multipotent, capable of differentiating in myocytes, smooth
muscle and endothelial cells [17]. Promising results have
been reported in preclinical studies [18], and results of phase I
clinical trials, started in 2009, are awaited with interest.
To date, ESC-derived cardiomyocytes [19] and ESC-
derived endothelial cells [20] have been successfully used
to treat heart disease in animal models. However several
problems are related to their use, including immunological
incompatibility with the host [21], the tendency to form
teratomas [22] and ethical controversies. Several studies
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190 Eur Radiol (2012) 22:189–204have been performed to manipulate the expression of
transcription factors with the goal of transforming somatic
cells (derived from an autologous source, such as keratino-
cytes and fat stromal cells) into induced pluripotent stem
cells (iPS) [23]. These cells possess the same advantages as
ESC, without the associated immunological and ethical
complications. Cardiomyocytes have been successfully
obtained from iPS in vitro [24] and their transplantation in
animal models of infarction resulted in improved myocardial
function [25].
To summarise, ESC and iPS have the greater potential
for cardiomyogenesis, while the formation of new cardio-
myocytes by transdifferentiation of SM and BMC has so far
not been supported with convincing evidence. It should be
noted that several studies have reported moderate improve-
ments in whole cardiac function after transplantation of SM
and BMC [7, 26]. It has been demonstrated that SCs are
responsible for paracrine effects, consisting of the release of
various cytokines or growth factors (eg. VEGF, bFGF) that
increase collateral perfusion and neoangiogenesis and influ-
ence the contractile characteristics of chronically failing
myocardium [26].
Imaging of stem cells
The ability to image and monitor the biodistribution,
viability and possibly the differentiation status of implanted
SCs is of massive clinical and research benefit. All of the
pre-clinical and clinical imaging techniques have been
leveraged towards this goal; each providing unique advan-
tages and limitations. Figure 1 illustrates the major
paradigms for the labelling of SC for detection by the
various imaging approaches. Table 2 reports the most
important preclinical studies in the field. Table 3 summarises
the most relevant features of each imaging technique.
MRI
Magnetic resonance imaging (MRI) is a widely established
technique for the evaluation of cardiac anatomy and
function, often through the addition of paramagnetic
contrast material [27]. Taking advantage of its excellent
spatial (10–100 μm [small animal MRI]); 500–1500 μm
[clinical]) and temporal resolution SC labelled with super-
paramagnetic and paramagnetic agents can be visualised
[28, 29]. Multispectralnon-
1H MR imaging (specifically
19F)
has also been exploited to enable tracking of transplanted
cells.
Superparamagnetic iron oxide nanoparticles
Superparamagnetic iron oxide (SPIO) nanoparticles provide
labelled cells with a large magnetic moment and are
detectable by MR imaging devices or benchtop relax-
ometers. SPIO functions by acting as magnetic inhomo-
geneities, locally disturbing the magnetic field. This
Fig. 1 Schematic representation of the current technologies available
for stem cell (SC) tracking. Before implantation SC can be passively
loaded with: a superparamagnetic nanoparticles that allow for the MR
detection of labelled cells as areas of signal loss; b radiolabelled PET
or SPECT probes. c Reporter gene approaches consist of the
introduction through viral or non-viral-vectors of a reporter gene driven
by a constitutive or inducible promoter. The reporter gene undergoes
transcription to mRNA, which is translated into a protein that can be: 1)
an enzyme (as HSV1-tk or luciferase), 2) a receptor (as transferrin
receptor or hSSTR [human somatostatin receptor]) 3) a transporter
(hNIS [human sodium iodide symporter]) 4) intracellular iron storage
protein (ferritin). When a complementary reporter probe is administered,
it concentrates or activates only at the site where the reporter gene is
expressed. The level of probe accumulation is proportional to the level
of reporter gene expression and can be monitored to evaluate the
number of cells or the induction of a specific reporter gene
Eur Radiol (2012) 22:189–204 191T
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S
P
I
O
I
n
t
r
a
m
y
o
c
a
r
d
i
a
l
-
d
i
r
e
c
t
D
e
t
e
c
t
i
o
n
u
p
t
o
4
w
e
e
k
s
b
y
M
R
I
.
L
V
E
F
i
d
e
n
t
i
c
a
l
b
e
t
w
e
e
n
t
h
e
t
r
a
n
p
l
a
n
t
e
d
g
r
o
u
p
a
n
d
c
o
n
t
r
o
l
.
T
e
r
r
o
v
i
t
i
s
e
t
a
l
.
[
4
5
]
r
a
t
h
C
D
C
r
C
D
C
S
P
I
O
I
n
t
r
a
m
y
o
c
a
r
d
i
a
l
-
d
i
r
e
c
t
S
i
g
n
a
l
v
o
i
d
p
e
r
s
i
s
t
e
d
a
f
t
e
r
3
w
e
e
k
s
i
n
b
o
t
h
s
y
n
g
e
n
e
i
c
a
n
d
x
e
n
o
g
e
n
e
i
c
c
e
l
l
i
m
p
l
a
n
t
a
t
i
o
n
.
I
m
m
u
n
o
h
i
s
t
o
c
h
e
m
i
s
t
r
y
i
d
e
n
t
i
f
i
e
s
t
h
e
i
r
o
n
c
o
n
t
a
i
n
i
n
g
c
e
l
l
s
a
s
m
a
c
r
o
p
h
a
g
e
s
.
R
a
d
i
o
n
u
c
l
i
d
e
C
h
i
n
e
t
a
l
.
[
6
2
]
s
w
i
n
e
M
S
C
1
1
1
I
n
-
o
x
i
n
e
I
n
t
r
a
v
e
n
o
u
s
S
i
g
n
i
f
i
c
a
n
t
l
u
n
g
a
c
t
i
v
i
t
y
t
h
a
t
o
b
s
c
u
r
e
d
t
h
e
a
s
s
e
s
s
m
e
n
t
o
f
m
y
o
c
a
r
d
i
a
l
c
e
l
l
t
r
a
c
k
i
n
g
.
B
r
e
n
n
e
r
e
t
a
l
.
[
6
3
]
r
a
t
H
P
C
-
C
D
3
4
+
1
1
1
I
n
-
o
x
i
n
e
I
n
t
r
a
c
a
v
i
t
a
r
y
(
l
e
f
t
v
e
n
t
r
i
c
u
l
u
m
)
I
m
p
a
i
r
m
e
n
t
o
f
c
e
l
l
p
r
o
l
i
f
e
r
a
t
i
o
n
a
n
d
d
i
f
f
e
r
e
n
t
i
a
t
i
o
n
i
n
d
u
c
e
d
b
y
1
1
1
I
n
-
o
x
i
n
e
.
A
t
9
6
h
o
n
l
y
1
%
o
f
r
a
d
i
o
a
c
t
i
v
i
t
y
w
a
s
d
e
t
e
c
t
e
d
i
n
t
h
e
h
e
a
r
t
.
B
l
a
c
k
w
o
o
d
[
6
5
]
d
o
g
B
M
C
1
1
1
I
n
-
t
r
o
p
o
l
o
n
e
I
n
t
r
a
m
y
o
c
a
r
d
i
a
l
-
d
i
r
e
c
t
V
i
a
b
i
l
i
t
y
a
t
d
a
y
6
a
f
t
e
r
i
n
t
r
a
m
y
o
c
a
r
d
i
a
l
i
n
j
e
c
t
i
o
n
w
a
s
c
a
l
c
u
l
a
t
e
d
t
o
b
e
7
5
%
.
T
e
r
r
o
v
i
t
i
s
e
t
a
.
.
[
8
2
]
r
a
t
r
C
D
C
1
8
F
-
F
D
G
I
n
t
r
a
m
y
o
c
a
r
d
i
a
l
-
d
i
r
e
c
t
D
i
f
f
e
r
e
n
t
r
e
t
e
n
t
i
o
n
v
a
l
u
e
s
w
e
r
e
o
b
s
e
r
v
e
d
a
t
1
h
a
f
t
e
r
i
n
j
e
c
t
i
o
n
o
f
c
e
l
l
s
w
i
t
h
n
o
r
m
a
l
c
o
n
d
i
t
i
o
n
(
1
7
.
8
%
±
7
.
3
)
,
a
r
r
e
s
t
e
d
h
e
a
r
t
(
7
5
.
8
%
±
1
8
.
3
)
,
a
d
e
n
o
s
i
n
e
i
n
j
e
c
t
i
o
n
(
3
5
.
4
%
±
5
.
3
)
a
n
d
a
d
e
n
o
s
i
n
e
p
l
u
s
f
i
b
r
i
n
g
l
u
e
(
3
9
.
3
%
±
1
1
.
6
)
.
M
i
t
c
h
e
l
l
e
t
a
l
.
[
6
6
]
d
o
g
E
P
C
1
1
1
I
n
-
t
r
o
p
o
l
o
n
e
I
n
t
r
a
m
y
o
c
a
r
d
i
a
l
-
p
e
r
c
u
t
a
n
e
o
u
s
1
5
d
a
y
s
a
f
t
e
r
i
n
t
r
a
m
y
o
c
a
r
d
i
a
l
i
n
j
e
c
t
i
o
n
S
P
E
C
T
/
C
T
i
m
a
g
i
n
g
d
e
m
o
n
s
t
r
a
t
e
d
c
o
m
p
a
r
a
b
l
e
d
e
g
r
e
e
s
o
f
r
e
t
e
n
t
i
o
n
:
5
7
%
±
1
5
f
o
r
t
h
e
s
u
b
e
p
i
c
a
r
d
i
a
l
i
n
j
e
c
t
i
o
n
s
a
n
d
5
4
%
±
2
6
f
o
r
t
h
e
s
u
b
e
n
d
o
c
a
r
d
i
a
l
i
n
j
e
c
t
i
o
n
s
.
M
u
l
t
i
m
o
d
a
l
T
e
r
r
o
v
i
t
i
s
e
t
a
l
.
.
r
a
t
r
C
D
C
9
9
m
T
c
,
1
2
4
I
;
h
N
I
S
I
n
t
r
a
m
y
o
c
a
r
d
i
a
l
-
d
i
r
e
c
t
D
e
t
e
c
t
i
o
n
u
p
t
o
6
d
a
y
s
a
f
t
e
r
i
n
j
e
c
t
i
o
n
a
n
d
t
h
e
i
r
p
r
e
s
e
n
c
e
v
a
l
i
d
a
t
e
d
b
y
e
x
v
i
v
o
i
m
a
g
i
n
g
a
n
d
q
P
C
R
.
Q
i
a
o
e
t
a
l
.
[
9
8
]
r
a
t
m
E
S
C
S
P
I
O
;
H
S
V
1
-
t
k
+
1
8
F
-
F
H
B
G
I
n
t
r
a
m
y
o
c
a
r
d
i
a
l
-
d
i
r
e
c
t
I
n
c
r
e
a
s
i
n
g
1
8
F
-
F
H
B
G
u
p
t
a
k
e
u
p
t
o
4
w
e
e
k
s
.
M
o
s
t
o
f
t
h
e
S
P
I
O
w
e
r
e
c
o
n
t
a
i
n
e
d
i
n
i
n
f
i
l
t
r
a
t
i
n
g
m
a
c
r
o
p
h
a
g
e
s
a
t
w
e
e
k
4
.
T
e
r
a
t
o
m
a
f
o
r
m
a
t
i
o
n
.
I
n
c
r
e
a
s
e
d
L
V
E
F
.
O
n
l
y
<
0
.
5
%
o
f
t
h
e
i
m
p
l
a
n
t
e
d
c
e
l
l
w
e
r
e
c
a
r
d
i
o
m
y
o
c
y
t
e
s
.
C
h
a
p
o
n
e
t
a
l
.
[
1
1
5
]
r
a
t
r
B
M
C
S
P
I
O
;
1
8
F
-
F
D
G
I
n
t
r
a
m
y
o
c
a
r
d
i
a
l
-
d
i
r
e
c
t
M
R
I
d
e
t
e
c
t
i
o
n
o
f
S
P
I
O
l
a
b
e
l
l
e
d
c
e
l
l
s
g
r
a
f
t
e
d
i
n
t
h
e
h
e
a
r
t
u
p
t
o
6
w
e
e
k
s
,
c
o
n
f
i
r
m
e
d
b
y
h
y
s
t
o
l
o
g
y
.
A
t
1
w
e
e
k
i
n
c
r
e
a
s
e
d
1
8
F
-
F
D
G
u
p
t
a
k
e
i
n
B
M
C
i
m
p
l
a
n
t
e
d
h
e
a
r
t
v
s
c
o
n
t
r
o
l
.
N
o
i
m
p
r
o
v
e
m
e
n
t
o
f
h
e
a
r
t
f
u
n
c
t
i
o
n
.
H
i
g
u
c
h
i
e
t
a
l
.
[
9
9
]
r
a
t
h
E
P
C
S
P
I
O
;
N
I
S
+
1
2
4
I
I
n
t
r
a
m
y
o
c
a
r
d
i
a
l
-
d
i
r
e
c
t
R
a
p
i
d
d
e
c
r
e
a
s
e
o
f
1
2
4
I
u
p
t
a
k
e
a
f
t
e
r
d
a
y
3
.
S
i
g
n
a
l
n
o
t
d
e
t
e
c
t
a
b
l
e
a
t
d
a
y
7
.
M
R
I
s
i
g
n
a
l
v
o
i
d
r
e
m
a
i
n
e
d
u
n
c
h
a
n
g
e
d
t
h
r
o
u
g
h
o
u
t
t
h
e
f
o
l
l
o
w
-
u
p
p
e
r
i
o
d
.
H
i
s
t
o
l
o
g
y
c
o
n
f
i
r
m
e
d
t
h
e
p
r
e
s
e
n
c
e
o
f
t
r
a
n
s
p
l
a
n
t
e
d
c
e
l
l
s
o
n
d
a
y
1
b
u
t
n
o
t
o
n
d
a
y
7
,
w
h
e
n
i
r
o
n
w
a
s
c
o
n
t
a
i
n
e
d
o
n
l
y
i
n
r
e
s
i
d
e
n
t
m
a
c
r
o
p
h
a
g
e
s
.
L
i
e
t
a
l
.
[
1
1
6
]
r
a
t
R
C
S
C
F
l
u
c
+
D
-
L
u
c
i
f
e
r
i
n
;
1
8
F
-
F
D
G
P
E
T
;
e
c
h
o
c
a
r
d
i
o
g
r
a
p
h
y
;
M
R
I
I
n
t
r
a
m
y
o
c
a
r
d
i
a
l
-
d
i
r
e
c
t
I
m
p
l
a
n
t
e
d
c
e
l
l
s
d
e
t
e
c
t
e
d
u
p
t
o
7
w
e
e
k
s
b
y
b
i
o
l
u
m
i
n
e
s
c
e
n
c
e
.
N
o
i
m
p
r
o
v
e
m
e
n
t
i
n
c
a
r
d
i
a
c
f
u
n
c
t
i
o
n
a
s
s
e
s
s
e
d
b
y
1
8
F
-
F
D
G
P
E
T
,
M
R
I
,
e
c
h
o
c
a
r
d
i
o
g
r
a
m
a
n
d
i
n
v
a
s
i
v
e
h
e
m
o
d
y
n
a
m
i
c
p
r
e
s
s
u
r
e
v
o
l
u
m
e
-
a
n
a
l
y
s
i
s
.
B
M
C
(
b
o
n
e
m
a
r
r
o
w
d
e
r
i
v
e
d
S
t
e
m
C
e
l
l
s
)
;
M
S
C
m
e
s
e
n
c
h
y
m
a
l
s
t
e
m
c
e
l
l
s
;
m
E
S
C
(
m
o
u
s
e
e
m
b
r
y
o
n
i
c
s
t
e
m
c
e
l
l
s
)
;
h
C
D
C
(
h
u
m
a
n
c
a
r
d
i
a
c
d
e
r
i
v
e
d
s
t
e
m
c
e
l
l
s
)
,
r
C
D
C
(
r
a
t
c
a
r
d
i
a
c
d
e
r
i
v
e
d
s
t
e
m
c
e
l
l
s
)
;
H
P
C
(
h
e
m
a
t
o
p
o
i
e
t
i
c
p
r
o
g
e
n
i
t
o
r
c
e
l
l
s
)
;
h
E
P
C
,
h
u
m
a
n
E
n
d
o
t
h
e
l
i
a
l
P
r
o
g
e
n
i
t
o
r
C
e
l
l
s
;
R
C
S
C
(
r
e
s
i
d
e
n
t
c
a
r
d
i
a
c
s
t
e
m
c
e
l
l
s
)
;
N
I
S
(
s
o
d
i
u
m
i
o
d
i
d
e
s
y
m
p
o
r
t
e
r
)
;
F
l
u
c
(
f
i
r
e
f
l
y
l
u
c
i
f
e
r
a
s
e
)
;
h
N
I
S
(
h
u
m
a
n
s
o
d
i
u
m
-
i
o
d
i
d
e
s
y
m
p
o
r
t
e
r
;
M
I
,
M
y
o
c
a
r
d
i
a
l
i
n
f
a
r
c
t
i
o
n
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a
b
l
e
3
W
h
a
t
t
o
i
m
a
g
e
a
n
d
h
o
w
t
o
i
m
a
g
e
I
m
a
g
i
n
g
m
o
d
a
l
i
t
y
S
p
a
t
i
a
l
r
e
s
o
l
u
t
i
o
n
(
m
m
)
S
e
n
s
i
t
i
v
i
t
y
(
m
o
l
/
L
)
C
e
l
l
M
a
n
i
p
u
l
a
t
i
o
n
W
h
a
t
t
o
i
m
a
g
e
H
o
w
t
o
i
m
a
g
e
A
d
v
a
n
t
a
g
e
s
D
i
s
a
d
v
a
n
t
a
g
e
s
F
l
u
o
r
e
s
c
e
n
c
e
I
m
a
g
i
n
g
F
R
I
:
2
–
3
m
m
;
F
M
T
:
1
m
m
1
0
−
9
–
1
0
−
1
2
C
e
l
l
s
l
a
b
e
l
e
d
w
i
t
h
n
e
a
r
-
i
n
f
r
a
r
e
d
p
r
o
b
e
s
(
f
l
u
o
r
o
c
h
r
o
m
e
s
,
Q
u
a
n
t
u
m
d
o
t
s
,
e
t
c
.
)
R
e
s
i
d
e
n
c
e
,
h
o
m
i
n
g
,
q
u
a
n
t
i
f
i
c
a
t
i
o
n
(
F
M
T
)
D
i
r
e
c
t
i
m
a
g
i
n
g
;
a
t
N
I
R
w
a
v
e
l
e
n
g
h
t
s
c
a
n
i
m
a
g
e
d
e
e
p
t
i
s
s
u
e
M
u
l
t
i
p
l
e
x
e
d
i
m
a
g
i
n
g
N
o
t
s
u
i
t
a
b
l
e
f
o
r
c
l
i
n
i
c
a
l
t
r
a
n
s
l
a
t
i
o
n
;
r
e
l
a
t
i
v
e
l
y
l
o
w
s
p
a
t
i
a
l
r
e
s
o
l
u
t
i
o
n
B
i
o
l
u
m
i
n
e
s
c
e
n
c
e
I
m
a
g
i
n
g
3
–
5
1
0
−
1
5
–
1
0
−
1
7
C
e
l
l
s
t
r
a
n
s
d
u
c
e
d
t
o
e
x
p
r
e
s
s
l
u
c
i
f
e
r
a
s
e
R
e
s
i
d
e
n
c
e
,
h
o
m
i
n
g
,
v
i
a
b
i
l
i
t
y
,
d
i
f
f
e
r
e
n
t
i
a
t
i
o
n
,
q
u
a
n
t
i
f
i
c
a
t
i
o
n
A
f
t
e
r
s
y
s
t
e
m
i
c
i
n
j
e
c
t
i
o
n
o
f
D
-
L
u
c
i
f
e
r
i
n
e
o
r
C
o
e
l
e
n
t
e
r
a
z
i
n
e
E
a
s
y
,
h
i
g
h
s
e
n
s
i
t
i
v
i
t
y
,
h
i
g
h
-
t
h
r
o
u
g
h
p
u
t
,
l
o
w
c
o
s
t
;
a
s
s
e
s
s
m
e
n
t
o
f
c
e
l
l
v
i
a
b
i
l
i
t
y
N
o
t
s
u
i
t
a
b
l
e
f
o
r
c
l
i
n
i
c
a
l
t
r
a
n
s
l
a
t
i
o
n
;
s
u
r
f
a
c
e
i
m
a
g
i
n
g
;
r
e
l
a
t
i
v
e
l
y
l
o
w
s
p
a
t
i
a
l
r
e
s
o
l
u
t
i
o
n
;
r
e
q
u
i
r
e
s
c
o
m
p
l
e
t
e
l
y
d
a
r
k
e
n
v
i
r
o
n
m
e
n
t
P
E
T
1
-
2
(
μ
P
E
T
)
;
6
–
1
0
(
c
l
i
n
i
c
a
l
P
E
T
)
1
0
−
1
1
–
1
0
−
1
2
C
e
l
l
s
l
o
a
d
e
d
w
i
t
h
1
8
F
-
F
D
G
;
6
4
C
u
l
a
b
e
l
l
e
d
c
o
m
p
o
u
n
d
s
R
e
s
i
d
e
n
c
e
,
h
o
m
i
n
g
,
q
u
a
n
t
i
f
i
c
a
t
i
o
n
D
i
r
e
c
t
i
m
a
g
i
n
g
H
i
g
h
s
e
n
s
i
t
i
v
i
t
y
,
t
r
a
n
s
l
a
t
i
o
n
a
l
R
a
d
i
a
t
i
o
n
;
o
n
l
y
s
h
o
r
t
t
e
r
m
c
e
l
l
t
r
a
c
k
i
n
g
C
e
l
l
s
t
r
a
n
s
d
u
c
e
d
t
o
e
x
p
r
e
s
s
P
E
T
r
e
p
o
r
t
e
r
g
e
n
e
s
(
H
S
V
1
t
k
,
H
S
V
1
-
s
r
3
9
t
k
)
R
e
s
i
d
e
n
c
e
,
h
o
m
i
n
g
,
d
i
f
f
e
r
e
n
t
i
a
t
i
o
n
,
q
u
a
n
t
i
f
i
c
a
t
i
o
n
,
A
f
t
e
r
s
y
s
t
e
m
i
c
i
n
j
e
c
t
i
o
n
o
f
c
o
r
r
e
s
p
o
n
d
e
n
t
r
a
d
i
o
l
a
b
e
l
l
e
d
p
r
o
b
e
(
1
8
F
-
F
H
B
G
,
1
8
F
-
F
E
A
U
,
e
t
c
.
)
H
i
g
h
s
e
n
s
i
t
i
v
i
t
y
,
l
o
n
g
t
e
r
m
c
e
l
l
t
r
a
c
k
i
n
g
;
a
s
s
e
s
s
m
e
n
t
v
i
a
b
i
l
i
t
y
R
a
d
i
a
t
i
o
n
;
n
e
e
d
t
o
t
r
a
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Eur Radiol (2012) 22:189–204 193leads to enhanced dephasing of protons, resulting in
decreased signal intensity on T2-weighted and T2*-weighted
images(Figs.2 and 3). These nanoparticles often consist of a
core of iron oxide (magnetite and/or maghemite) with a
polymeric or polysaccharide coating. They are widely
viewed to be biocompatible, have a limited effect on cell
function and can be synthesized to be biodegradable.
According to their size (diameter), these are classified as
ultrasmall paramagnetic iron oxide (USPIO, <10 nm),
monocrystalline iron oxide particles (MION, or cross-
linked CLIO; 10–30 nm), standard superparamagnetic iron
oxide (SPIO; 60–150 nm) and micron-sized iron oxide
particles (MPIO, 0.7–1.6 μm). Of note, ferucarbotran
(Resovist®; Bayer Schering Pharma, Berlin, Germany) and
ferumoxides (Feridex I.V.®, Advanced Magnetic Indus-
tries, Cambridge, Maryland, USA; Endorem®, Guerbet,
Gorinchem, the Netherlands) have been approved by the
FDA for contrast enhanced-MRI imaging of liver tumors
[30] and metastatic involvement of lymph nodes [31].
Cell uptake is mediated through the size and electrostatic
charge conditions of the SPIO [32], schematically illustrat-
ed in Fig. 1a. Further, loading can be augmented through
the addition of cell penetrating peptides, electroporation or
transfection agents [33].
Studies reported that SPIOs do not affect cell viability,
proliferation, differentiation or migration [34–38]. Howev-
er, recent work has raised several concerns, such as
decreased MSC migration and colony-formation ability
[39], and interference with cell function [40, 41]. A major
issue beyond potential cellular effects is the question of
contrast specificity to the presence of cells. Namely, the
hypointense signal is maintained at a site regardless of cell
viability and SPIO are present not necessarily within
implanted SC at longer time points [42], but rather in
phagocytosing monocytes following SC death [43]. Recently,
Winter et al. reported the absence of any discrimination
between healthy successfully engrafted SC and dead SC
phagocytosed by macrophages within the heart. In particular,
no differences in signal voids up to more than 40 days were
observed with dead and viable cells recipient with respect to
size, number and localisation [44]. Similarly, it has been
demonstrated that MRI overestimates the SPIO labelled SC
survival after transplantation in the heart [45]. Furthermore,
SPIO-induced hypointensity can sometimes be difficult to
interpret because it may be obscured by the presence of
endogenous blood derivates, such as hemosiderin [46]. The
clinical translation of SPIO for cell tracking is further
reduced now that ferumoxides (Feridex® or Endorem®) are
no longer available in the USA and Europe. However, the
use of iron oxides approaches should not be discouraged
as they provide very high sensitivities. New compounds
with improved tissue clearance properties (therefore
higher specificities) are awaited from material sciences
research.
Fig. 2 Anatomical and functional MR evaluation after transplantion
of adipose-derived stem cell (ASC) and relative controls: cell culture
medium (CCM), and untreated hearts. The CCM-treated and untreated
hearts showed evident thinning in the anterior wall of the left
ventricle. From Wang, L. et al. Am J Physiol Heart Circ Physiol
297: H1020-H1031 2009 [15] (with permission)
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Cell labelling with “positive contrast” such as gadolinium
(Gd) chelates and manganese (Mn) chloride compounds
allow the visualisation of SC as hyperintense signal on
T1-weighted images. Internalization of Gd can be
accomplished by exposure of cells to Gd chelates or
through the use of liposomal formulations [33]. MRI
sensitivity in the detection of Gd-labelled cells is lower
compared to SPIO-labelled cells and is dependent upon
contrast behaviour and relaxivity in the cellular compart-
ment (endosomes) in which they are localised [47, 48].
This is a result of the reduced water accessibility to
chelated ions following intracellular concentration, resulting
in decreased relaxivity. To overcome these issues several
approaches have been considered to drive the endosomal
escape of paramagnetic compounds [49]. Furthermore, safety
issues might be related to the rapid dechelation of
compounds at the low pH of lysosomes and endosomes
raising concerns related to free Gd
3+ ions [50].
Sub-millimolar concentrations of Mn chloride (MnCl2)
have been sufficient to enable SC labelling and detection
for both in vitro and in vivo MR, with no detectable toxicity.
Also in the same study the potential of MnCl2 labelling in the
assessment of SC viability by T1 and T2 mapping was
investigated in in vitro studies [51]. Mn-oxide nanoparticles
have recently been used to label and track implanted glioma
cells. Of considerable interest, the feasibility of successfully
tracking two cell populations simultaneously has been
suggested, where one is labelled with Mn-Oxide and the
other with SPIOs [52]. These and other paramagnetic ion
techniques offer the hope that positive contrast approaches
will enable sensitive MR tracking of SC in vivo. Novel
nanotechnology approaches are becoming available for stem
cell tracking such as gadolinium-containing carbon nano-
capsules (Gadonanotubes), whose T1 relaxivity is greater
than that of any known material to date (outperforming
clinically available Gd-based contrast agents by 40-fold)
[53]. They will definitely play a role in the future of
imaging sciences as soon as their toxicity profiles,
currently under investigation, have been clarified.
19FM R
Similar to the imaging of relaxation of
1H from water,
19F
can be used as the basis of the signal for MR
spectroscopy and image formation. While this technique
is not implemented widely in the clinic, there are unique
advantages to fluorine-MR that make it an attractive
option for SC tracking in myocardial applications.
19Fi s
not present naturally in soft tissues therefore its signal is
exclusively derived from the exogenous contrast agent
Fig. 3 Longitudinal BLI and MRI of H9c2 cells after transplantation.
BLI shows a robust distinct heart signal on day 1 (red arrow),
compared to no discernable signal in a representative control rat
having received non-labelled cells (top panel, left). The signal
increases slightly on day 3 but decreases rapidly to near background
levels by day 6. MRI imaging of a representative rat injected with the
same amount of cells labelled with Feridex shows a large hypointense
signal (red arrow) in the anterolateral wall of the myocardium. The
size of the signal decreases slightly over time, and the signal persists
for at least 80 days post cell injection. No signal is observed in control
rat that received non-labelled cells (bottom panel, left) Chen, I. Yet al.
Mol Imaging Biol. 2009 May-Jun;11:178–87. [42] (with permission)
Eur Radiol (2012) 22:189–204 195applied, be it a perfluorocarbon particle or fluorinated
nucleosides [54].
19F MRI can be used with existing
1H
imaging hardware since
19Fa n d
1H gyromagnetic ratios
differ by only 6%.
Importantly,
19F signal can be overlaid on
1H-MR
anatomical images for a highly selective, high-resolution
map of cell transplantation. This technique allows for
quantitative determination of the cell population [55]. A
perfluorocarbon particle loaded cell scheme has been used
to show the unequivocal and unique signature for SC,
enabling spatial cell localization via
19F- MRI and quanti-
tation via
19F-spectroscopy [56]. Perfluorocarbons have
been extensively studied and used as blood substitutes,
therefore their toxicity profiles are known.
19F cell tracking
has attracted interest, but is still at an early stage of
development. It should be noted that this method does
suffer from the drawback of lower sensitivity requiring
longer imaging times. Efforts are underway to address these
deficits including imaging hardware, imaging sequences,
and label improvement and
19F MR imaging is expected to
play a role in cell tracking in the future [54].
Radionuclide imaging
Imaging of SC has also taken advantage of the high
sensitivity (10
-10−10
−12 mol/L vs 10
−3–10
−5 mol/L of MRI)
and quantitative (acute cell retention as a percentage of the
net injected dose per weight, [%ID/g]) characteristics of
radionuclide imaging [57]. However, PET and particularly
SPECT have inferior spatial resolution (1–2 mm) compared
with MRI. Moreover, radionuclide-labelled cells can only
be visualised as long as the radioactivity is still detectable
(e.g.
18F: 110 min;
111In: 2.8 days;
99mTc: 6 h). This sets an
appreciable limitation on the radioisotopes direct label-
ling value for medium- and long-term SC transplant
monitoring. SPECT has been largely used to investigate
the short-term fate of transplanted cells labelled with
radioactive compounds such as
111In-oxine [58–63],
99mTc-
hexamethylprophylene amine oxine (HMPAO) [64]o r
111In-
tropolone [65, 66]. A persistent limitation for deployment of
SPECT is that in order to generate useful (quantitative)
i m a g e sw i t h i nar e a s o n a b l et i m ef r a m e ,t h ea d m i n i s t r a -
tion of relatively large doses of radioactivity are
required. This poses the concern of inherent radiation
damage (reduced viability and proliferation). In the case
of
111In, Auger electrons are also emitted leading to
adverse biological effects in very short distances (from the
nm to μm range). Brenner et al., demonstrated that despite
the homing of progenitor cells into the infarction area, cell
labelling with
111In-oxine impairs significantly the viability,
proliferation and differentiation at 48 h after implantation
[63]. Similar results were observed after exposure of murine
haematopoietic progenitor cells at even much lower levels of
radioactivity [67]. The use of other compounds, such as
111In-tropolone, inhibited cell proliferation 3 days after
labeling [68]. To abrogate these effects, it has been suggested
that only a fraction of the SC population be labelled [69].
Regardless of the method used, very few studies have
reported the absence of any cell function impairment [58,
62]. These studies underline the need for further in vitro
studies considering different SC, exposed to different activi-
ties and importantly following the same labelling protocol.
Positron emission tomography (PET) has been regarded
as having higher sensitivity (2 to 3 orders of magnitude)
and better spatial and temporal resolution than SPECT [70].
18F-Fluorodeoxyglucose (
18F-FDG) has been used for cell
labelling and short term imaging in preclinical [71] and
clinical settings (Fig. 4)[ 72, 73]. After intracoronary
injection all stem cells showed poor engraftment regardless
of cell type and number of implanted cells [61, 72, 73]. In
all cases intravenous injection of SC did not show
detectable homing of cells to the myocardium [72, 73].
Augmenting the higher sensitivity, the wider availability
of hybrid PET-CT systems allows for a combination of
anatomical non-invasive coronary angiography and cell
tracking. This multimodal imaging capability and clinical
availability are tempered somewhat by the the short half life
of
18F. Isotopes with longer half life, such as
64Cu (12.7 h)
Fig. 4 PET/CT images of a patient with hystory of anterior wall
infarction. After percutaneous intervention 18 F-FDG labelled cells
were implanted via intracoronary catheter and images obtained at 2 hrs
after the procedure. Total amount of SC at the injection site was
measured (2.1% of injected dose). From Kang et al. J Nucl Med 2006;
47:1295–1301. [73] (with permission)
196 Eur Radiol (2012) 22:189–204have been suggested [74]. However, with radionuclide
based techniques pursued so far, only the immediate fate of
transplanted stem cells can be interrogated.
Reporter genes
Reportergene approaches have significant potential toreveal
insights into the mechanisms and fate of SC therapies. The
reporter gene paradigm requires often the appropriate
combination of reporter transgene and a reporter probe, such
that the reporter gene product has to interact with an imaging
probe (optical, nuclear, magnetic) and when this event occurs
the signal may be detected and quantified with the
corresponding imaging technique (Fig. 1c).
Several advantages of reporter gene approaches have been
described [75]. Namely, this system identifies with exquisite
specificity only viable cells (which actively contain the gene
product) and allows long term tracking of transduced SC
(circumventing issues of probe dilution with cellular prolifer-
ation). Reporter genes can be designed as “constitutive”
whose signal is “always turned on” (suitable for the
evaluation of transplantation, migration and proliferation of
stably transduced SC) or “inducible” reporter gene which is
activated and regulated by specific endogenous transcription
factors and promoters [75, 76] providing a non-invasive
readout of information regarding SC differentiation.
The most widely used reporter gene for radiotracer based
imaging is HSV1-tk (Herpes simplex virus type 1 thymi-
dine kinase) and its mutant, the HSV1-sr39tk. Unlike
mammalian TK1, this enzyme efficiently phosphorylates
purine and pyrimidine analogues which results in trapping
and accumulation of these ligands. It has been successfully
used in association with
18Fo r
124I- 2 ′-deoxy-2′-fluoro-5-
iodo-1-[β]-D-arabinofuranosyluracil (
18F-FIAU and
124I-
FIAU),
18F2 ′-fluoro-5-ethyl-1-[β]-D-arabinofuranosyluracil
(
18F-FEAU), and 9-(4-[
18F]fluoro-3-hydroxymethylbutyl)
guanine (
18F-FHBG) [75, 77].
Wu et al., pioneered the reporter gene approach in the
heart by imaging in vivo transplanted cells (expressing
luciferase or HSV1-sr39tk) up to 2 weeks by
18F-FHBG
PET imaging or BLI [78]. Furthermore, Cao et al., reported
survival and proliferation (through increasing signal up
to 4 weeks) of murine ES stably transduced with a triple
fusion reporter gene, enabling simultaneous PET, biolu-
minescence and fluorescence imaging [79].
Despite the advantage of signal amplification (through
probe phosphorylation and accumulation within cells) of
HSV-tk based approaches, its immunogenicity might limit
use in humans [80]. To overcome this limitation, the human
mitochondrial thymidine kinase type 2 (hTK2) have been
proposed [81]. An alternative is the sodium iodide symporter
[51] as a PET and SPECT reporter gene used in conjunction
with
124Io r
99mTc (pertechnetate), respectively [75, 82].
Here, despite the lack of probe/signal amplification observed
in receptor- and transporter-based techniques (as
124Io r
99mTc are free to diffuse out of the cells), hNIS is not
immunogenic (since it is expressed in the thyroid, stomach
salivary gland, choroid plexus but not in the heart) and does
not require complex radiosynthesis of the probes. Neverthe-
less, in reporter gene approach for the imaging of SC-based
cardiac therapy several important issues remain. First, the
non-physiological expression of reporter gene proteins may
perturb the critical SC cellular and therapeutic functions. To
be fully reliable, this system has to guarantee the long term
expression of the reporter gene in the proliferating popula-
tion. Adenoviral transfection is hampered by episomal gene
expression (the reporter gene is not integrated in the
chromatin, and because they are not replicating, they become
diluted with cell proliferation) and by immunogenicity
(leakiness of immunogenic adenoviral proteins that can lead
to an immune response) [83]. On the other hand, lentiviral
vectors accomplish the integration of the reporter gene in the
host cell chromatin allowing stable expression in dividing
cells [84] and circumventing immunogenicity [85]. Even
when lentiviral vectors are used however, transgene expres-
sion can be silenced by DNA methylation especially when
strong promoters, such as CMV, are used to drive the
expression of the reporter gene [86]. The integration of the
reporter gene within the genome has raised concerns about
the risk of mutagenesis and potential oncogenicity [87].
The imaging of differentiation in vivo was recently
investigated by Kammili et al., by employing a novel dual-
reporter mouse embryonic SC line. Here, enhanced yellow
fluorescent protein (EYFP) was used as a “constitutive
reporter”, and the firefly luciferase reporter as an “inducible
reporter”. This latter gene was under the control of the
cardiac sodium-calcium exchanger 1 (Ncx1) promoter
which showed increased activity upon differentiation of
SC into beating cardiomyocytes [76].
Several candidates have been proposed as MRI reporter
genes such as β-galactosidase, transferrin receptor, ferritin,
MagA and lysine-rich proteins [88, 89]. Recently, SM
engineered to express ferritin have been transplanted in
infarcted heart and detected (as decreased signal up to 25%)
up to 3 weeks [90]. Several studies have been reported with
the application of MR reporters, however, none of these
strategies have led to a significant number of follow-up
studies. This is due to the low sensitivity of MRI for
imaging of gene activity in vivo.
Optical imaging
BLI
In contrast to the immediate clinical impact of magnetic and
nuclear tomographic imaging, optical imaging techniques
Eur Radiol (2012) 22:189–204 197such as bioluminescence, planar and fluorescence-mediated
tomography have been largely restricted to use in preclinical
models. Bioluminescence imaging is commonly used for cell
tracking in SC transplantation studies [78, 79, 91]( F i g s .3
and 5). SC are transduced with a luciferase gene and
implanted in the recipient animal. Following injection, the
probe (D-Luciferin) is oxidized only in the cells expressing
luciferase in presence of ATP, O2 and Mg
2+ resulting in light
photons being emitted (which can be detected by ultrasen-
sitive charge-coupled device [CCD] cameras). BLI has many
advantages: it is highly sensitive, quantitative, simple and
inexpensive. However, the barrier to clinical translation lies
in the inherent limitations imposed by poor tissue penetration
(1–2 cm) (allowing only surface imaging), high rates of
scattering of visible wavelength photons on the human scale
and low resolution (3–5 mm) (which hamper the exact
evaluation of the exact location of the cells) [57].
Fluorescence
DirectlabellingofSCwithfluorescentprobesforvisualisation
in vitro and in vivo has been fueled by the availability of near
infrared (NIR) probes, as their spectral properties are matched
to lower tissue attenuation in the so-called NIR-window. This
provides greater signal penetration of tissue through
reduced light absorption and tissue scattering. Therefore
they have clinical potential, however limited to near-
surface or intraoperative imaging stem cell tracking.
Near infrared imaging provides high sensitivity as well
as tomographic capabilities and there is no evidence at
Fig. 5 Bioluminescence imaging of CD34+ cells expressing the
TGL gene (HSV1-tk, e-GFP, f-luc) and implanted in the heart of a
SCID mouse. Systemically administered luciferin is activated
(oxidized by luciferase) in the injected cells. Here we see follow-
up of implanted cells up to 52 weeks post-implantation. Measure-
ment of emitted light in CD34+ implants is higher than in controls
(PBS injection). From Wang, J. et al. Circ Res 2010;106:1904–1911.
[91] (with permission)
198 Eur Radiol (2012) 22:189–204present that dyes released after cell death are taken up by
macrophages. Intracoronary delivery of MSC labelled with
the NIR dye IR-786 has been successfully tracked in a
swine model of myocardial infarction and sensitivity of
10.000 cells has been reported [92].
Quantum dots (QD) are a class of inorganic, fluorescent
nanoparticles that have been successfully used to label SC.
Biocompatibility of QD at low concentrations has been
demonstrated in vitro in MSC cultures [93]a n dt h e
absence of adverse effects on cell viability, proliferation or
differentiation reported [94]. One of the most attractive
qualities of these nanoparticles is their capacity for
multiplexed imaging. The tracking of different cell
populations is concurrently achieved by labelling cells
with different QDs. Multiplex optical imaging of QD-
labelled embryonic stem cells have been reported up to
14 days from injection in mice [94]. Moreover, it has been
shown that single QD-MSC can be detected in histological
sectionsfor atleast8 weeksafter delivery [95]. The long-term
effects on SC functionality are still unknown, however
concerns are related to their metallic core include its exposure
or dissolution which may result in toxicity, particularly from
heavy metals such as Pb, Cd and Se [96, 97]
Fig. 6 Co-registration of MRI a and
18F-FHBG PET b of murine
ESC transduced with HSV1-sr39tk and passively labelled with SPIO.
Images depict the presence and tracking of SC 14 days after
transplantation. This hybrid imaging c approach leverages the
advantages of each technique; the fine anatomical resolution of MR
and the specificity of nuclear imaging. From Qiao et al. Radiology
250:3, 821–829. [98] (with permission)
Fig. 7 a MRI (upper row),
124I-PET (middle row), and fusion images
13N-NH3 (gray scale)/
124I (colour scale) (bottom row) of rat heart
1 day after injection of EPC labelled with iron (left), NIS only
(middle), or both iron and NIS (right). Signal void of iron-labeled
HEPCs is observed by MRI whereas HEPCs expressing NIS showed
focal
124I accumulation by PET. b Consecutive myocardial sections
showing the presence of transplanted cells: autoradiography for
124I
uptake mediated by NIS reporter (left), X-galactosidase staining for
LacZ gene expression of graft cells (middle), and Prussian blue
staining for iron particle detection (right). c Mean±SD time–activity
curves after
124I administration of transplanted cell and left ventricular
blood measured by PET. From Higuchi T et al. J Nucl Med, 50:1088–
1094. [99] (with permission)
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The possibility of complementing the sensitivity of radio-
nuclide or optical techniques with the high-resolution
anatomical information from MRI is a key player in the
clinical and research future of SC tracking. To date, the
most interesting approach has been to develop transgenic
cells that carry an optical/nuclear imaging reporter together
with passive labelling with MRI contrast agents before
administration. Qiao et al. assessed the survival and
proliferation of SPIO-labelled murine ESC transduced with
HSV1-sr39tk longitudinally (4 weeks) following injection
into the healthy or infarcted myocardium. ESCs grafted and
underwent proliferation, as shown by increasing uptake of
18F-FHBG in PET (Fig. 6) and decreasing the size of MR
hypointense areas due to SPIO dilution. Interestingly at
week 4 the majority of SPIO labels (released upon cell
death) were phagocytized and contained in infiltrating
macrophages rather than the ESC. Despite teratoma
formation, a slight increase in left ventricular ejection
fraction in ESC-treated animals was observed, mainly as a
result of paracrine effects, as cardiac differentiation of
implanted ESC was less than 0.5% [98]. In a similar study
human EPC derived from CD34+ mononuclear cells of
umbilical cord blood were transduced with NIS reporter
gene and labelled with SPIOs. Rapid loss of viable grafted
cells was observed, as
124I PET accumulation decreased
below detection limit at 3 days after transplant. However,
MRI signal void resulting from SPIO persisted,
corresponding to retention of SPIOs within macrophages
after graft cells’ death (Fig. 7)[ 99]. Triple fusion reporter
gene have been widely applied for multimodality fluores-
cence, bioluminescence and nuclear imaging approaches
[100]. Recently, in a quad-modal optical, PET, CT and MRI
coregistration approach CD34+ cells were transduced with a
triple fusion reporter gene (e-GFP, f-Luc and HSV1-tk).
Bioluminescence imaging revealed that cells persisted in the
heart up to 12 months and MRI studies reported improve-
ment in the left ventricular ejection fraction was preserved
up to 6 months (Fig. 5)[ 91].
Conclusion
Many of the approaches to image stem cells are promising
but further work is required before a wide clinical
translation becomes reality. Beyond the unresolved safety
and ethical issues, crucial questions: “What is the best route
for cell delivery ?”“ What kind and how many cells ?” and
“When to inject ?” remain.
It has become clear that there is no single ‘best method’
in cell tracking. Rather there is an array of high sensitivity,
high spatial resolution and functional techniques that work
best in combination. The persistent trends in molecular
imaging are: to focus on the development of novel MR-
compatible probes able to monitor and track with sufficient
sensitivity and specificity the fate of transplanted cells, new
PET/SPECT reporter genes with lessened immunogenicity
and oncogenicity issues, and the application of related
radioprobes with better pharmacokinetic profiles.
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